Evidence map›Paper›PMID 37781187›Full record

ArticleFrontiers in oncology2023

Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure.

Laura Botta, Tomohiro Matsuda, Hadrien Charvat, Chun-Ju Chiang, Wen-Chung Lee, Anna Jacoba van Gestel, Frank Martin, Gijs Geleijnse, Matteo Cellamare, Simone Bonfarnuzzo and 12 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Laura BottaEvaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tomohiro MatsudaInsititute of Cancer Control, National Cancer Center, Tokyo, Japan.
Hadrien CharvatFaculty of International Liberal Arts, Juntendo University, Tokyo, Japan.
Chun-Ju ChiangTaiwan Cancer Registry Center, and Institute of Epidemiology and Preventive Medicine, Taipei, Taiwan.
Wen-Chung LeeTaiwan Cancer Registry Center, and Institute of Epidemiology and Preventive Medicine, Taipei, Taiwan.
Anna Jacoba van GestelIKNL, Department of Research & Development, Netherlands Comprehensive Cancer Organisation, Utrech, Netherlands.
Frank MartinIKNL, Department of Research & Development, Netherlands Comprehensive Cancer Organisation, Utrech, Netherlands.
Gijs GeleijnseIKNL, Department of Research & Development, Netherlands Comprehensive Cancer Organisation, Utrech, Netherlands.
Matteo CellamareIKNL, Department of Research & Development, Netherlands Comprehensive Cancer Organisation, Utrech, Netherlands.
Simone BonfarnuzzoAnalytical Epidemiology and Health Impact Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Rafael Marcos-GrageraEpidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi), Universitat de Girona, Girona, Spain.
Marcela GuevaraBiomedical Network Research Centers of Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Mohsen MousaviEast Switzerland Cancer Registry, St. Gallen, Switzerland.
Stephanie CraigPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
Jessica RodriguesCancer Epidemiology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC) & RISE@CI-IPOP (Health Research Network), Porto, Portugal.
Jordi Rubió-CasadevallMedical Oncology Department, Catalan Institute of Oncology, Girona, Spain.
Lisa LicitraHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Stefano CavalieriHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Carlo ResteghiniHead and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Gemma GattaEvaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Annalisa TramaEvaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
RARECAREnet working group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The head and neck cancers (HNCs) incidence differs between Europe and East Asia. Our objective was to determine whether survival of HNC also differs between European and Asian countries. Methods: We used population-based cancer registry data to calculate 5-year relative survival (RS) for the oral cavity, hypopharynx, larynx, nasal cavity, and major salivary gland in Europe, Taiwan, and Japan. We modeled RS with a generalized linear model adjusting for time since diagnosis, sex, age, subsite, and histological grouping. Analyses were performed using federated learning, which enables analyses without sharing sensitive data. Findings: Five-year RS for HNC varied between geographical areas. For each HNC site, Europe had a lower RS than both Japan and Taiwan. HNC subsites and histologies distribution and survival differed between the three areas. Differences between Europe and both Asian countries persisted even after adjustments for all HNC sites but nasal cavity and paranasal sinuses, when comparing Europe and Taiwan. Interpretation: Survival differences can be attributed to different factors including different period of diagnosis, more advanced stage at diagnosis, or different availability/access of treatment. Cancer registries did not have stage and treatment information to further explore the reasons of the observed survival differences. Our analyses have confirmed federated learning as a feasible approach for data analyses that addresses the challenges of data sharing and urge for further collaborative studies including relevant prognostic factors.

Indexed as

federated learning approachgeographical differenceshead and neck cancerspopulation-based cancer registrysurvival

Identifiers

PMID37781187
PMCPMC10534949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.